Table 5.
Clinical features of polycythemia vera patients experiencing and not experiencing thrombotic events
| Variable | With TE (n = 48) | Without TE (n = 76) | p value |
|---|---|---|---|
| Age, yr | 64.8 ± 12. 8 | 60.4 ± 14.8 | 0.091 |
| Male sex | 33 (68.8) | 46 (60.5) | 0.354 |
| Palpable splenomegaly | 3 (6.3) | 6 (7.9) | 0.731 |
| Laboratory findings | |||
| WBC, × 109/L | 15.8 ± 8.5 | 14.9 ± 6.3 | 0.492 |
| Monocyte, × 109/L | 0.8 ± 0.5 | 0.7 ± 0.3 | 0.124 |
| Hemoglobin, g/dL | 17.7 ± 3.0 | 18.4 ± 2.3 | 0.140 |
| Platelet, × 109/L | 544.2 ± 347.3 | 490.2 ± 244.8 | 0.325 |
| LDH, × UNL | 1.4 ± 0.6 | 1.3 ± 0.6 | 0.849 |
| Driver gene mutation | |||
| JAK2V617F | 36/39 (92.3) | 59/67 (88.1) | 0.449 |
| JAK2 exon12 | 1/39 (2.6) | 4/67 (6.0) | 0.648 |
| Comorbidity | |||
| Hypertension | 20 (62.5) | 44 (57.9) | 0.611 |
| Diabetes mellitus | 15 (31.3) | 15 (19.7) | 0.145 |
| Chronic kidney disease | 10 (20.8) | 21 (27.6) | 0.394 |
| Smoking | 21 (43.8) | 29 (38.2) | 0.536 |
| Hemorrhagic event | 7 (14.6) | 6 (7.9) | 0.236 |
| Follow-up duration, yr | 7.2 ± 5.7 | 8.2 ± 6.5 | 0.344 |
Values are presented as mean ± SD or number (%).
TE, thrombotic events; WBC, white blood cell; LDH, lactate dehydrogenase; UNL, upper normal limit; JAK2, Janus kinase 2.